Monday, September 23, 2019
- 1:45pm-3:15pm
-
NILO-PD: A Phase 2A Study of Nilotinib in Patients with Advanced Parkinson’s Disease: Study Design and Status Update
Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3
- 1:45pm-3:15pm
-
NKX2-1-Related Disorder with Cerebral Folate Deficiency
Rare Genetic and Metabolic Diseases · Les Muses Terrace, Level 3
- 1:45pm-3:15pm
-
Non-CpG methylation in the FXN gene in patients with Friedreich’s ataxia
Ataxia · Les Muses, Level 3
- 1:45pm-3:15pm
-
Non-Medical Switching: Impact on Movement Disorders Patients’ Access and Care
Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3
- 1:45pm-3:15pm
-
Normative Curves for Selected Unified Huntington Disease Rating Scale Measures
Huntington’s Disease · Agora 3 West, Level 3
- 1:45pm-3:15pm
-
Normative Reference for Timed Up and Go Test (TUG) in Young Indian Adults- Preliminary Results
Ataxia · Les Muses, Level 3
- 1:45pm-3:15pm
-
Novel exploratory outcome assessments in GENERATION HD1
Huntington’s Disease · Agora 3 West, Level 3
- 1:45pm-3:15pm
-
Novel Mutation of NUS1 Gene Presenting With Developmental And Epileptic Encephalopathy and Movement Disorders
Rare Genetic and Metabolic Diseases · Les Muses Terrace, Level 3
- 1:45pm-3:15pm
-
Novel p.Pro193Arg missense mutation in ABCD1-gene associated with phenotype of ALD/AMN: a case report
Genetics · Les Muses Terrace, Level 3
- 1:45pm-3:15pm
-
Objective quantifiable assessment of nocturnal movements in patients with Parkinson’s disease using a wearable sensor
Other · Agora 2 West, Level 2
- «Previous Page
- 1
- …
- 45
- 46
- 47
- 48
- 49
- …
- 75
- Next Page»